［1］ LANG J M， HARRISON M R. Pazopanib for the treatment of patients with advanced renal cell carcinoma［J］. Clin Med Insights Oncol， 2010， 1（4）:95-105.
［2］ CLARK P E. Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma［J］. Biologics，2010，9（4）:187-97.
［3］ TAILOR T D， HANNA G， YARMOLENKO P S Y， et al. Effect of pazopanib on tumor microenvironment and liposome delivery［J］. Mol Cancer Ther June， 2010，9 （6）:1798 -1808.
［4］ HURWITZ H I， DOWLATI A， SAINI S， et al. Phase I trial of pazopanib in patients with advanced cancer［J］. Clin Cancer Res， 2009， 15（12）: 4220-4227.
［5］ Votrient Glaro smithkline[EB/OL]. http://us.gsk.com/products/assets/us_votrient.pdf. 2010-04.
［6］ Votrient Tablets. Product information［EB/OL］. www. medicines. org. au/files/gwpvotri. 2010-06-22.
［7］ HEATH E I， CHIOREAN E G， SWEENEY C J， et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors［J］. Clin Pharmacol Ther， 2010， 27（10）:1-6.
［8］ HURWITZ H， DOWLATI A， SAVAGE S. Safety，tolerability and pharmacokinetics of oral administration of GW-786034 in pts with solid tumors［J］. Clin Oncol， 2005， 23（16）:3012-3023.
［9］ SANFORD M， KEATING G M. Pazopanib in advanced renal cell carcinoma ［J］. Bio Drugs，2010， 24（5）:279-286.
［10］ WARD J E， STADLER W M. Pazopanib in remal cell carcinoma［J］. Cin Cancer Res， 2010，16 （24）:5923-5927.
［11］ KEISNER S V， SHAN S R. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma［J］. Drugs， 2011，71（4）:443-454.